CHEMICAL AND PHYSICAL PROPERTIES
| Solubility | Soluble |
|---|
COMPUTED DESCRIPTORS
| Molecular Weight | 3961 g/mol |
|---|---|
| XLogP3 | -20.9 |
| Hydrogen Bond Donor Count | 61 |
| Hydrogen Bond Acceptor Count | 60 |
| Rotatable Bond Count | 145 |
| Exact Mass | 3959.2738250 g/mol |
| Monoisotopic Mass | 3958.2704702 g/mol |
| Topological Polar Surface Area | 1740 Ų |
| Heavy Atom Count | 279 |
| Formal Charge | 0 |
| Complexity | 9310 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 34 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently-Bonded Unit Count | 1 |
| Compound Is Canonicalized | Yes |
PRODUCT INTRODUCTION
description
Abaloparatide is an analog of PTHrP (parathyroid hormone-related protein). It was approved in April 28, 2017 by the FDA (as Tymlos) for the treatment of postmenopausal women with osteoporosis at high risk for fracture. Abaloparatide is a synthetic peptide that is related to hPTHrP and has demonstrated in preclinical testing the potential to widen the anabolic window for bone therapeutics, stimulating bone formation with a limited effect on bone resorption and mineral mobilization. This could enable improved convenience over currently available anabolic therapies, resulting in greater compliance and, ultimately, greater benefit to patients. In October 2022, the EMA's Committee for Medicinal Products for Human Use (CHMP) recommended abaloparatide be granted marketing authorization in Europe for the treatment of osteoporosis in postmenopausal women at increased risk of fracture. In December 2022, the FDA indication for abaloparatide was expanded to include male patients in addition to postmenopausal women.